Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma
暂无分享,去创建一个
[1] Manojkumar Saranathan,et al. Variable spatiotemporal resolution three‐dimensional dixon sequence for rapid dynamic contrast‐enhanced breast MRI , 2014, Journal of magnetic resonance imaging : JMRI.
[2] D. Appelbaum,et al. FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer , 2013, Cancer medicine.
[3] U. Tateishi,et al. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course , 2012, BMC Cancer.
[4] T. Powles,et al. Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.
[5] S. Fosså,et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).
[6] U. Tateishi,et al. Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report , 2010, BMC Cancer.
[7] U. Tateishi,et al. Evaluation of Response to Multikinase Inhibitor in Metastatic Renal Cell Carcinoma by FDG PET/Contrast-Enhanced CT , 2010, Clinical nuclear medicine.
[8] Rakesh Kumar,et al. SIGNIFICANCE OF 18F‐FLUORODEOXYGLUCOSE POSITRON‐EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR THE POSTOPERATIVE SURVEILLANCE OF ADVANCED RENAL CELL CARCINOMA , 2010, BJU international.
[9] C. Sternberg,et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Boijsen,et al. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography , 2009, Nuclear medicine communications.
[12] E. Hindié,et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. , 2009, Cancer biotherapy & radiopharmaceuticals.
[13] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[14] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[15] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[16] J. Larkin,et al. Kinase inhibitors in the treatment of renal cell carcinoma. , 2006, Critical reviews in oncology/hematology.
[17] E. Eisenhauer,et al. RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.
[18] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[19] T. Olencki,et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[21] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[22] M. Aapro,et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. , 2009, Critical reviews in oncology/hematology.
[23] C. Porta,et al. Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial , 2008 .
[24] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.